Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
85 hedge funds and large institutions have $95.4M invested in Y-mAbs Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 19 closing their positions.
2,400% more call options, than puts
Call options by funds: $50K | Put options by funds: $2K
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
2% more capital invested
Capital invested by funds: $93.6M → $95.4M (+$1.81M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.73% less ownership
Funds ownership: 44.21% → 43.48% (-0.73%)
7% less funds holding
Funds holding: 91 → 85 (-6)
32% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.75M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.32M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.32M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$936K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$821K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.67M |
| 2 |
Millennium Management
New York
|
-$2.06M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.95M |
| 4 |
E
Ergoteles
New York
|
-$936K |
| 5 |
BlackRock
New York
|
-$889K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PMEF
101
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$14.6K | -2,999 | Closed |
|
102
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$8.27K | -1,694 | Closed |
|
103
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$7K | -1,443 | Closed |
|
104
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$90 | -22 | -35% |
|
YMAB Hedge Fund Activity: Q1 2023 in Review
85 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2023, worth a combined $95.4M — up 1.9% from $93.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of YMAB and 13 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 32 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $1.75M. The largest seller was Citadel Advisors, cutting an estimated $2.67M.
- 85 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2023, down from 91 in Q4 2022.
- Funds reported $95.4M of Y-mAbs Therapeutics stock for Q1 2023, up 1.9% quarter-over-quarter.
- 13 funds opened new Y-mAbs Therapeutics positions in Q1 2023 and 19 closed out, a net change of -6 holders.
- The largest Y-mAbs Therapeutics buyer in Q1 2023 was AIGH Capital Management, an estimated $1.75M added.
- The largest Y-mAbs Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $2.67M sold.
Based on aggregated 13F filings for Q1 2023.